查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1601121

核子医学市场：按产品、应用、类型和最终用户 - 2025-2030 年全球预测

Nuclear Medicine Market by Product (Diagnostic Products, Therapeutic Products), Application (Bone Metastasis, Cardiology, Endocrine Tumor), Type, End-Users - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 182 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年核医市场价值为51.4亿美元，预计2024年将达到55.1亿美元，复合年增长率为7.35%，到2030年将达到84.5亿美元。

核子医学是一门医学影像专业，它使用少量的放射性物质（称为放射性药物）来诊断和治疗各种疾病，包括癌症、心臟病和神经系统疾病。对核子医学的需求源于其能够提供对器官和组织生理功能的独特见解，从而实现早期诊断和量身定制的治疗计划。 PET和SPECT扫描等技术用于准确的疾病检测，放射性同位素疗法用于治疗。最终用途范围从医院和诊所到诊断中心和研究机构。推动核医学市场的主要成长要素包括成像技术的技术进步、慢性病的流行以及对早期诊断益处的认识不断提高。此外，个人化医疗的日益普及和新型放射性药物的开发提供了巨大的潜在机会。为了抓住这些机会，产业参与者应投资创新的放射性同位素研发，并专注于利用人工智慧来改善成像结果和患者治疗结果。然而，挑战包括高昂的设备成本、严格的监管要求以及某些放射性同位素的供应有限，这可能会限制市场成长。非侵入性显像模式的开发和新的治疗诊断应用等创新被认为是克服这些挑战的有希望的途径。该市场竞争激烈且充满活力，其特点是研究机构和医疗保健提供者之间不断进步和策略联盟。公司可以透过专注于新兴市场、解决供应链问题并确保遵守监管标准来获得真正的优势。这些策略倡议对于在市场格局中持续取得成功和保持领导地位至关重要，因为市场存在取决于对技术和监管条件变化快速反应的能力。

主要市场统计
基准年[2023] 51.4亿美元
预测年份 [2024] 55.1亿美元
预测年份 [2030] 84.5亿美元
复合年增长率（%） 7.35%

市场动态：揭示快速发展的核子医学市场的关键市场洞察

供需的动态交互作用正在改变核医市场。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时也能帮助企业了解消费行为及其对製造业的影响。

  • 市场驱动因素
    • 全球癌症发生率和盛行率不断上升
    • 越来越多地使用 PET 和 SPECT 来诊断心臟和神经系统疾病
    • 国际组织支持核子医学的努力和意识提升
  • 市场限制因素
    • 核医学半衰期短
  • 市场机会
    • 治疗诊断学在核子医学中日益普及
    • 持续的产品开发和专利技术进步
  • 市场挑战
    • 新兴国家缺乏核医学知识、培训和可得性
    • 全球缺乏熟练的放射科医生和专家

波特五力：驾驭核医市场的策略工具

波特的五力框架是理解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解核子医学市场的外部影响

外部宏观环境因素在塑造核医市场的表现动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并为他们做出积极主动的决策做好准备。

市场占有率分析 了解核子医学市场的竞争状况

对核子医学市场的详细市场占有率分析可以对供应商绩效进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 定位矩阵核子医学市场供应商的绩效评估

FPNV定位矩阵是评估核子医学市场供应商的重要工具。此矩阵允许业务组织根据供应商的商务策略和产品满意度评估供应商，从而做出符合其目标的明智决策。四个象限清楚且准确地划分供应商，帮助使用者辨识最能满足其策略目标的合作伙伴和解决方案。

本报告提供了涵盖关键重点领域的全面市场分析：

1. 市场渗透率：对当前市场环境的详细回顾，包括行业主要企业的大量资料。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，以帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 世界各地的癌症发生率和盛行率正在上升
      • PET 和 SPECT 在诊断心臟和神经系统疾病的使用增加
      • 国际组织的努力与支持核子医学的认识
    • 抑制因素
      • 核医学半衰期短
    • 机会
      • 治疗诊断学在核子医学中日益普及
      • 持续的产品开发和专利技术进步
    • 任务
      • 新兴国家缺乏核子医学知识、培训和可用性
      • 全球缺乏熟练的放射科医生和医生
  • 市场区隔分析
    • 产品：诊断产品在核子医学的意义
    • 最终用户：医院和诊断中心的各种应用
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境
  • 客户客製化

第六章核子医学市场：副产品

  • 诊断产品
    • PET
      • F-18
      • SR-82/RB-82
    • SPECT
      • GA-67
      • I-123
      • TC-99m
      • TL-201
  • 治疗产品
    • α发射体
    • β放射体
      • I-131
      • Lu-117
      • 重新 186
      • SM-153
      • Y-90
    • 放射线治疗
      • 铯131
      • 碘125
      • 铱192
      • 钯103

第七章 核子医学市场：依应用分类

  • 骨转移
  • 心臟病学
  • 内分泌肿瘤
  • 淋巴瘤
  • 肿瘤学
  • 甲状腺

第八章核子医学市场：依类型

  • 诊断
    • PET检查
    • SPECT程式
  • 治疗性的
    • α发射体
    • β发射器程式
    • 放射线治疗程序

第九章核医市场：依最终使用者分类

  • 医院和诊断中心
  • 调查机构

第十章美洲核子医学市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十一章亚太核子医学市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十二章 欧洲、中东和非洲核子医学市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十三章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
    • Shine 与 Nucleus RadioPharma 签署供应协议
    • ITM 与加拿大核能研究所组成新公司
    • Life Healthcare 将收购南非核子医学业务

公司名单

  • Actinium Pharmaceuticals, Inc.
  • Bayer AG
  • BJ Madan & Co.
  • Bracco SpA
  • BWX Technologies, Inc. by Framatome
  • Cardinal Health, Inc.
  • Curium
  • Eckert & Ziegler Radiopharma GmbH
  • Eczacibasi Monrol Nuclear Products Co.
  • GE Healthcare
  • IBA Radiopharma Solutions
  • Institute of Isotopes Co., Ltd.
  • Isotope Joint Stock Company
  • Isotopia Molecular Imaging
  • Jubilant DraxImage, Inc.
  • Lantheus Holdings, Inc.
  • Nordic Nanovector ASA by Thor Medical
  • Nordion（Canada）Inc. by Sotera Health LLC
  • Northstar Medical Technologies LLC
  • Novartis AG
  • NTP Radioisotopes SOC Ltd.
  • PharmaLogic Holdings LLC
  • Radiopharm Theranostics Limited
  • SHINE Technologies, LLC
  • Sinotau Pharmaceuticals Group
Product Code: MRR-A339DAEFAF4C

The Nuclear Medicine Market was valued at USD 5.14 billion in 2023, expected to reach USD 5.51 billion in 2024, and is projected to grow at a CAGR of 7.35%, to USD 8.45 billion by 2030.

Nuclear medicine is a specialized area of medical imaging that uses small amounts of radioactive materials, known as radiopharmaceuticals, to diagnose and treat various diseases, including cancer, heart disease, and neurological disorders. The necessity of nuclear medicine arises from its ability to provide unique insights into the physiological function of organs and tissues, thus enabling earlier diagnosis and tailored treatment plans. Applications span diagnostic and therapeutic uses, where techniques like PET and SPECT scans are employed for precise disease detection, and radioisotope therapy is utilized in treatments. The end-use scope ranges from hospitals and clinics to diagnostic centers and research institutions. Key growth factors driving the nuclear medicine market include technological advancements in imaging techniques, a growing prevalence of chronic diseases, and increased awareness of the benefits of early diagnosis. Furthermore, increasing adoption of personalized medicine and the development of novel radiopharmaceuticals present significant potential opportunities. To capture these opportunities, industry players should focus on investing in R&D for innovative radioisotopes and leveraging AI to enhance imaging results and patient outcomes. However, challenges lie in the high cost of equipment, stringent regulatory requirements, and limited availability of certain radioisotopes, which can constrain market growth. Innovations, such as developing non-invasive imaging modalities and new theranostic applications, are seen as promising avenues for overcoming these challenges. The market is competitive and dynamic, characterized by continuous advancements and strategic collaborations among research institutions and healthcare providers. Companies can gain a substantial edge by focusing on emerging markets, addressing supply chain issues, and ensuring compliance with regulatory standards. Such strategic moves are essential for sustained success and leadership in the nuclear medicine landscape, where the ability to promptly adapt to technological and regulatory changes can define market presence.

KEY MARKET STATISTICS
Base Year [2023] USD 5.14 billion
Estimated Year [2024] USD 5.51 billion
Forecast Year [2030] USD 8.45 billion
CAGR (%) 7.35%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Nuclear Medicine Market

The Nuclear Medicine Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rising Incidence and Prevalence of Cancer Worldwide
    • Increasing Use of PET and SPECT to Diagnose Heart disease and Neurological Disorders
    • International Organizations' Initiatives and Awareness Supporting Nuclear Medicine
  • Market Restraints
    • Shorter Half-Life of Nuclear Medicine
  • Market Opportunities
    • Emerging Popularity of Theranostics in Nuclear Medicine
    • Continuous Product Developments and Advancements in Patented Technologies
  • Market Challenges
    • Lack of Knowledge, Training, and Availability of Nuclear Medicine in Developing Countries
    • Limited Availability of Skilled Radiologists and Practitioners Worldwide

Porter's Five Forces: A Strategic Tool for Navigating the Nuclear Medicine Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Nuclear Medicine Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Nuclear Medicine Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Nuclear Medicine Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Nuclear Medicine Market

A detailed market share analysis in the Nuclear Medicine Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Nuclear Medicine Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Nuclear Medicine Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Key Company Profiles

The report delves into recent significant developments in the Nuclear Medicine Market, highlighting leading vendors and their innovative profiles. These include Actinium Pharmaceuticals, Inc., Bayer AG, BJ Madan & Co., Bracco S.p.A., BWX Technologies, Inc. by Framatome, Cardinal Health, Inc., Curium, Eckert & Ziegler Radiopharma GmbH, Eczacibasi Monrol Nuclear Products Co., GE Healthcare, IBA Radiopharma Solutions, Institute of Isotopes Co., Ltd., Isotope Joint Stock Company, Isotopia Molecular Imaging, Jubilant DraxImage, Inc., Lantheus Holdings, Inc., Nordic Nanovector ASA by Thor Medical, Nordion (Canada) Inc. by Sotera Health LLC, Northstar Medical Technologies LLC, Novartis AG, NTP Radioisotopes SOC Ltd., PharmaLogic Holdings LLC, Radiopharm Theranostics Limited, SHINE Technologies, LLC, and Sinotau Pharmaceuticals Group.

Market Segmentation & Coverage

This research report categorizes the Nuclear Medicine Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Product, market is studied across Diagnostic Products and Therapeutic Products. The Diagnostic Products is further studied across PET and SPECT. The PET is further studied across F-18 and SR-82/RB-82. The SPECT is further studied across GA-67, I-123, TC-99m, and TL-201. The Therapeutic Products is further studied across Alpha Emitters, Beta Emitters, and Brachytherapy. The Beta Emitters is further studied across I-131, Lu-117, Re-186, SM-153, and Y-90. The Brachytherapy is further studied across Cesium-131, Iodine-125, Iridium-192, and Palladium-103.
  • Based on Application, market is studied across Bone Metastasis, Cardiology, Endocrine Tumor, Lymphoma, Oncology, and Thyroid.
  • Based on Type, market is studied across Diagnostic and Therapeutic. The Diagnostic is further studied across PET Procedures and SPECT Procedures. The Therapeutic is further studied across Alpha Emitter Procedures, Beta Emitter Procedures, and Brachytherapy Procedures.
  • Based on End-Users, market is studied across Hospitals & Diagnostic Centers and Research institutes.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising Incidence and Prevalence of Cancer Worldwide
      • 5.1.1.2. Increasing Use of PET and SPECT to Diagnose Heart disease and Neurological Disorders
      • 5.1.1.3. International Organizations' Initiatives and Awareness Supporting Nuclear Medicine
    • 5.1.2. Restraints
      • 5.1.2.1. Shorter Half-Life of Nuclear Medicine
    • 5.1.3. Opportunities
      • 5.1.3.1. Emerging Popularity of Theranostics in Nuclear Medicine
      • 5.1.3.2. Continuous Product Developments and Advancements in Patented Technologies
    • 5.1.4. Challenges
      • 5.1.4.1. Lack of Knowledge, Training, and Availability of Nuclear Medicine in Developing Countries
      • 5.1.4.2. Limited Availability of Skilled Radiologists and Practitioners Worldwide
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Product: Significance of diagnostic products in nuclear medicines
    • 5.2.2. End-Users: Diverse applications in hospitals and diagnostic centers
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental
  • 5.5. Client Customization

6. Nuclear Medicine Market, by Product

  • 6.1. Introduction
  • 6.2. Diagnostic Products
    • 6.2.1. PET
      • 6.2.1.1. F-18
      • 6.2.1.2. SR-82/RB-82
    • 6.2.2. SPECT
      • 6.2.2.1. GA-67
      • 6.2.2.2. I-123
      • 6.2.2.3. TC-99m
      • 6.2.2.4. TL-201
  • 6.3. Therapeutic Products
    • 6.3.1. Alpha Emitters
    • 6.3.2. Beta Emitters
      • 6.3.2.1. I-131
      • 6.3.2.2. Lu-117
      • 6.3.2.3. Re-186
      • 6.3.2.4. SM-153
      • 6.3.2.5. Y-90
    • 6.3.3. Brachytherapy
      • 6.3.3.1. Cesium-131
      • 6.3.3.2. Iodine-125
      • 6.3.3.3. Iridium-192
      • 6.3.3.4. Palladium-103

7. Nuclear Medicine Market, by Application

  • 7.1. Introduction
  • 7.2. Bone Metastasis
  • 7.3. Cardiology
  • 7.4. Endocrine Tumor
  • 7.5. Lymphoma
  • 7.6. Oncology
  • 7.7. Thyroid

8. Nuclear Medicine Market, by Type

  • 8.1. Introduction
  • 8.2. Diagnostic
    • 8.2.1. PET Procedures
    • 8.2.2. SPECT Procedures
  • 8.3. Therapeutic
    • 8.3.1. Alpha Emitter Procedures
    • 8.3.2. Beta Emitter Procedures
    • 8.3.3. Brachytherapy Procedures

9. Nuclear Medicine Market, by End-Users

  • 9.1. Introduction
  • 9.2. Hospitals & Diagnostic Centers
  • 9.3. Research institutes

10. Americas Nuclear Medicine Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Nuclear Medicine Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Nuclear Medicine Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
    • 13.3.1. Shine Reaches Supply Agreement with Nucleus RadioPharma
    • 13.3.2. ITM and Canadian Nuclear Labs Launch New Company
    • 13.3.3. Life Healthcare Set to Acquire Nuclear-medicine Operation in SA

Companies Mentioned

  • 1. Actinium Pharmaceuticals, Inc.
  • 2. Bayer AG
  • 3. BJ Madan & Co.
  • 4. Bracco S.p.A.
  • 5. BWX Technologies, Inc. by Framatome
  • 6. Cardinal Health, Inc.
  • 7. Curium
  • 8. Eckert & Ziegler Radiopharma GmbH
  • 9. Eczacibasi Monrol Nuclear Products Co.
  • 10. GE Healthcare
  • 11. IBA Radiopharma Solutions
  • 12. Institute of Isotopes Co., Ltd.
  • 13. Isotope Joint Stock Company
  • 14. Isotopia Molecular Imaging
  • 15. Jubilant DraxImage, Inc.
  • 16. Lantheus Holdings, Inc.
  • 17. Nordic Nanovector ASA by Thor Medical
  • 18. Nordion (Canada) Inc. by Sotera Health LLC
  • 19. Northstar Medical Technologies LLC
  • 20. Novartis AG
  • 21. NTP Radioisotopes SOC Ltd.
  • 22. PharmaLogic Holdings LLC
  • 23. Radiopharm Theranostics Limited
  • 24. SHINE Technologies, LLC
  • 25. Sinotau Pharmaceuticals Group

LIST OF FIGURES

  • FIGURE 1. NUCLEAR MEDICINE MARKET RESEARCH PROCESS
  • FIGURE 2. NUCLEAR MEDICINE MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL NUCLEAR MEDICINE MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY END-USERS, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY END-USERS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. AMERICAS NUCLEAR MEDICINE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. AMERICAS NUCLEAR MEDICINE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. UNITED STATES NUCLEAR MEDICINE MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 17. UNITED STATES NUCLEAR MEDICINE MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC NUCLEAR MEDICINE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. ASIA-PACIFIC NUCLEAR MEDICINE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA NUCLEAR MEDICINE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA NUCLEAR MEDICINE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. NUCLEAR MEDICINE MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 23. NUCLEAR MEDICINE MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. NUCLEAR MEDICINE MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL NUCLEAR MEDICINE MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. NUCLEAR MEDICINE MARKET DYNAMICS
  • TABLE 7. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC PRODUCTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY PET, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY F-18, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY SR-82/RB-82, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY PET, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY SPECT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY GA-67, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY I-123, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY TC-99M, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY TL-201, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY SPECT, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY THERAPEUTIC PRODUCTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY ALPHA EMITTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY BETA EMITTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY I-131, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY LU-117, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY RE-186, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY SM-153, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY Y-90, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY BETA EMITTERS, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY BRACHYTHERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY CESIUM-131, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY IODINE-125, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY IRIDIUM-192, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 33. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY PALLADIUM-103, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 34. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY BRACHYTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 35. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY THERAPEUTIC PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 36. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 37. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY BONE METASTASIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 38. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY CARDIOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 39. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY ENDOCRINE TUMOR, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 40. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY LYMPHOMA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 41. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 42. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY THYROID, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 43. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 44. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 45. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY PET PROCEDURES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 46. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY SPECT PROCEDURES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 47. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC, 2018-2030 (USD MILLION)
  • TABLE 48. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY THERAPEUTIC, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 49. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY ALPHA EMITTER PROCEDURES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 50. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY BETA EMITTER PROCEDURES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 51. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY BRACHYTHERAPY PROCEDURES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 52. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
  • TABLE 53. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 54. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY HOSPITALS & DIAGNOSTIC CENTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 55. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 56. AMERICAS NUCLEAR MEDICINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 57. AMERICAS NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 58. AMERICAS NUCLEAR MEDICINE MARKET SIZE, BY PET, 2018-2030 (USD MILLION)
  • TABLE 59. AMERICAS NUCLEAR MEDICINE MARKET SIZE, BY SPECT, 2018-2030 (USD MILLION)
  • TABLE 60. AMERICAS NUCLEAR MEDICINE MARKET SIZE, BY THERAPEUTIC PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 61. AMERICAS NUCLEAR MEDICINE MARKET SIZE, BY BETA EMITTERS, 2018-2030 (USD MILLION)
  • TABLE 62. AMERICAS NUCLEAR MEDICINE MARKET SIZE, BY BRACHYTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 63. AMERICAS NUCLEAR MEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 64. AMERICAS NUCLEAR MEDICINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 65. AMERICAS NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC, 2018-2030 (USD MILLION)
  • TABLE 66. AMERICAS NUCLEAR MEDICINE MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
  • TABLE 67. AMERICAS NUCLEAR MEDICINE MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 68. AMERICAS NUCLEAR MEDICINE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 69. ARGENTINA NUCLEAR MEDICINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 70. ARGENTINA NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 71. ARGENTINA NUCLEAR MEDICINE MARKET SIZE, BY PET, 2018-2030 (USD MILLION)
  • TABLE 72. ARGENTINA NUCLEAR MEDICINE MARKET SIZE, BY SPECT, 2018-2030 (USD MILLION)
  • TABLE 73. ARGENTINA NUCLEAR MEDICINE MARKET SIZE, BY THERAPEUTIC PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 74. ARGENTINA NUCLEAR MEDICINE MARKET SIZE, BY BETA EMITTERS, 2018-2030 (USD MILLION)
  • TABLE 75. ARGENTINA NUCLEAR MEDICINE MARKET SIZE, BY BRACHYTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 76. ARGENTINA NUCLEAR MEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 77. ARGENTINA NUCLEAR MEDICINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 78. ARGENTINA NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC, 2018-2030 (USD MILLION)
  • TABLE 79. ARGENTINA NUCLEAR MEDICINE MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
  • TABLE 80. ARGENTINA NUCLEAR MEDICINE MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 81. BRAZIL NUCLEAR MEDICINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 82. BRAZIL NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 83. BRAZIL NUCLEAR MEDICINE MARKET SIZE, BY PET, 2018-2030 (USD MILLION)
  • TABLE 84. BRAZIL NUCLEAR MEDICINE MARKET SIZE, BY SPECT, 2018-2030 (USD MILLION)
  • TABLE 85. BRAZIL NUCLEAR MEDICINE MARKET SIZE, BY THERAPEUTIC PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 86. BRAZIL NUCLEAR MEDICINE MARKET SIZE, BY BETA EMITTERS, 2018-2030 (USD MILLION)
  • TABLE 87. BRAZIL NUCLEAR MEDICINE MARKET SIZE, BY BRACHYTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 88. BRAZIL NUCLEAR MEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 89. BRAZIL NUCLEAR MEDICINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 90. BRAZIL NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC, 2018-2030 (USD MILLION)
  • TABLE 91. BRAZIL NUCLEAR MEDICINE MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
  • TABLE 92. BRAZIL NUCLEAR MEDICINE MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 93. CANADA NUCLEAR MEDICINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 94. CANADA NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 95. CANADA NUCLEAR MEDICINE MARKET SIZE, BY PET, 2018-2030 (USD MILLION)
  • TABLE 96. CANADA NUCLEAR MEDICINE MARKET SIZE, BY SPECT, 2018-2030 (USD MILLION)
  • TABLE 97. CANADA NUCLEAR MEDICINE MARKET SIZE, BY THERAPEUTIC PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 98. CANADA NUCLEAR MEDICINE MARKET SIZE, BY BETA EMITTERS, 2018-2030 (USD MILLION)
  • TABLE 99. CANADA NUCLEAR MEDICINE MARKET SIZE, BY BRACHYTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 100. CANADA NUCLEAR MEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 101. CANADA NUCLEAR MEDICINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 102. CANADA NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC, 2018-2030 (USD MILLION)
  • TABLE 103. CANADA NUCLEAR MEDICINE MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
  • TABLE 104. CANADA NUCLEAR MEDICINE MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 105. MEXICO NUCLEAR MEDICINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 106. MEXICO NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 107. MEXICO NUCLEAR MEDICINE MARKET SIZE, BY PET, 2018-2030 (USD MILLION)
  • TABLE 108. MEXICO NUCLEAR MEDICINE MARKET SIZE, BY SPECT, 2018-2030 (USD MILLION)
  • TABLE 109. MEXICO NUCLEAR MEDICINE MARKET SIZE, BY THERAPEUTIC PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 110. MEXICO NUCLEAR MEDICINE MARKET SIZE, BY BETA EMITTERS, 2018-2030 (USD MILLION)
  • TABLE 111. MEXICO NUCLEAR MEDICINE MARKET SIZE, BY BRACHYTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 112. MEXICO NUCLEAR MEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 113. MEXICO NUCLEAR MEDICINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 114. MEXICO NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC, 2018-2030 (USD MILLION)
  • TABLE 115. MEXICO NUCLEAR MEDICINE MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
  • TABLE 116. MEXICO NUCLEAR MEDICINE MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 117. UNITED STATES NUCLEAR MEDICINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 118. UNITED STATES NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 119. UNITED STATES NUCLEAR MEDICINE MARKET SIZE, BY PET, 2018-2030 (USD MILLION)
  • TABLE 120. UNITED STATES NUCLEAR MEDICINE MARKET SIZE, BY SPECT, 2018-2030 (USD MILLION)
  • TABLE 121. UNITED STATES NUCLEAR MEDICINE MARKET SIZE, BY THERAPEUTIC PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 122. UNITED STATES NUCLEAR MEDICINE MARKET SIZE, BY BETA EMITTERS, 2018-2030 (USD MILLION)
  • TABLE 123. UNITED STATES NUCLEAR MEDICINE MARKET SIZE, BY BRACHYTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 124. UNITED STATES NUCLEAR MEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 125. UNITED STATES NUCLEAR MEDICINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 126. UNITED STATES NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC, 2018-2030 (USD MILLION)
  • TABLE 127. UNITED STATES NUCLEAR MEDICINE MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
  • TABLE 128. UNITED STATES NUCLEAR MEDICINE MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 129. UNITED STATES NUCLEAR MEDICINE MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 130. ASIA-PACIFIC NUCLEAR MEDICINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 131. ASIA-PACIFIC NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 132. ASIA-PACIFIC NUCLEAR MEDICINE MARKET SIZE, BY PET, 2018-2030 (USD MILLION)
  • TABLE 133. ASIA-PACIFIC NUCLEAR MEDICINE MARKET SIZE, BY SPECT, 2018-2030 (USD MILLION)
  • TABLE 134. ASIA-PACIFIC NUCLEAR MEDICINE MARKET SIZE, BY THERAPEUTIC PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 135. ASIA-PACIFIC NUCLEAR MEDICINE MARKET SIZE, BY BETA EMITTERS, 2018-2030 (USD MILLION)
  • TABLE 136. ASIA-PACIFIC NUCLEAR MEDICINE MARKET SIZE, BY BRACHYTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 137. ASIA-PACIFIC NUCLEAR MEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 138. ASIA-PACIFIC NUCLEAR MEDICINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 139. ASIA-PACIFIC NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC, 2018-2030 (USD MILLION)
  • TABLE 140. ASIA-PACIFIC NUCLEAR MEDICINE MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
  • TABLE 141. ASIA-PACIFIC NUCLEAR MEDICINE MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 142. ASIA-PACIFIC NUCLEAR MEDICINE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 143. AUSTRALIA NUCLEAR MEDICINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 144. AUSTRALIA NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 145. AUSTRALIA NUCLEAR MEDICINE MARKET SIZE, BY PET, 2018-2030 (USD MILLION)
  • TABLE 146. AUSTRALIA NUCLEAR MEDICINE MARKET SIZE, BY SPECT, 2018-2030 (USD MILLION)
  • TABLE 147. AUSTRALIA NUCLEAR MEDICINE MARKET SIZE, BY THERAPEUTIC PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 148. AUSTRALIA NUCLEAR MEDICINE MARKET SIZE, BY BETA EMITTERS, 2018-2030 (USD MILLION)
  • TABLE 149. AUSTRALIA NUCLEAR MEDICINE MARKET SIZE, BY BRACHYTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 150. AUSTRALIA NUCLEAR MEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 151. AUSTRALIA NUCLEAR MEDICINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 152. AUSTRALIA NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC, 2018-2030 (USD MILLION)
  • TABLE 153. AUSTRALIA NUCLEAR MEDICINE MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
  • TABLE 154. AUSTRALIA NUCLEAR MEDICINE MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 155. CHINA NUCLEAR MEDICINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 156. CHINA NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 157. CHINA NUCLEAR MEDICINE MARKET SIZE, BY PET, 2018-2030 (USD MILLION)
  • TABLE 158. CHINA NUCLEAR MEDICINE MARKET SIZE, BY SPECT, 2018-2030 (USD MILLION)
  • TABLE 159. CHINA NUCLEAR MEDICINE MARKET SIZE, BY THERAPEUTIC PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 160. CHINA NUCLEAR MEDICINE MARKET SIZE, BY BETA EMITTERS, 2018-2030 (USD MILLION)
  • TABLE 161. CHINA NUCLEAR MEDICINE MARKET SIZE, BY BRACHYTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 162. CHINA NUCLEAR MEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 163. CHINA NUCLEAR MEDICINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 164. CHINA NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC, 2018-2030 (USD MILLION)
  • TABLE 165. CHINA NUCLEAR MEDICINE MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
  • TABLE 166. CHINA NUCLEAR MEDICINE MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 167. INDIA NUCLEAR MEDICINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 168. INDIA NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 169. INDIA NUCLEAR MEDICINE MARKET SIZE, BY PET, 2018-2030 (USD MILLION)
  • TABLE 170. INDIA NUCLEAR MEDICINE MARKET SIZE, BY SPECT, 2018-2030 (USD MILLION)
  • TABLE 171. INDIA NUCLEAR MEDICINE MARKET SIZE, BY THERAPEUTIC PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 172. INDIA NUCLEAR MEDICINE MARKET SIZE, BY BETA EMITTERS, 2018-2030 (USD MILLION)
  • TABLE 173. INDIA NUCLEAR MEDICINE MARKET SIZE, BY BRACHYTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 174. INDIA NUCLEAR MEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 175. INDIA NUCLEAR MEDICINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 176. INDIA NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC, 2018-2030 (USD MILLION)
  • TABLE 177. INDIA NUCLEAR MEDICINE MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
  • TABLE 178. INDIA NUCLEAR MEDICINE MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 179. INDONESIA NUCLEAR MEDICINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 180. INDONESIA NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 181. INDONESIA NUCLEAR MEDICINE MARKET SIZE, BY PET, 2018-2030 (USD MILLION)
  • TABLE 182. INDONESIA NUCLEAR MEDICINE MARKET SIZE, BY SPECT, 2018-2030 (USD MILLION)
  • TABLE 183. INDONESIA NUCLEAR MEDICINE MARKET SIZE, BY THERAPEUTIC PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 184. INDONESIA NUCLEAR MEDICINE MARKET SIZE, BY BETA EMITTERS, 2018-2030 (USD MILLION)
  • TABLE 185. INDONESIA NUCLEAR MEDICINE MARKET SIZE, BY BRACHYTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 186. INDONESIA NUCLEAR MEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 187. INDONESIA NUCLEAR MEDICINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 188. INDONESIA NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC, 2018-2030 (USD MILLION)
  • TABLE 189. INDONESIA NUCLEAR MEDICINE MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
  • TABLE 190. INDONESIA NUCLEAR MEDICINE MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 191. JAPAN NUCLEAR MEDICINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 192. JAPAN NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 193. JAPAN NUCLEAR MEDICINE MARKET SIZE, BY PET, 2018-2030 (USD MILLION)
  • TABLE 194. JAPAN NUCLEAR MEDICINE MARKET SIZE, BY SPECT, 2018-2030 (USD MILLION)
  • TABLE 195. JAPAN NUCLEAR MEDICINE MARKET SIZE, BY THERAPEUTIC PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 196. JAPAN NUCLEAR MEDICINE MARKET SIZE, BY BETA EMITTERS, 2018-2030 (USD MILLION)
  • TABLE 197. JAPAN NUCLEAR MEDICINE MARKET SIZE, BY BRACHYTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 198. JAPAN NUCLEAR MEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 199. JAPAN NUCLEAR MEDICINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 200. JAPAN NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC, 2018-2030 (USD MILLION)
  • TABLE 201. JAPAN NUCLEAR MEDICINE MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
  • TABLE 202. JAPAN NUCLEAR MEDICINE MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 203. MALAYSIA NUCLEAR MEDICINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 204. MALAYSIA NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 205. MALAYSIA NUCLEAR MEDICINE MARKET SIZE, BY PET, 2018-2030 (USD MILLION)
  • TABLE 206. MALAYSIA NUCLEAR MEDICINE MARKET SIZE, BY SPECT, 2018-2030 (USD MILLION)
  • TABLE 207. MALAYSIA NUCLEAR MEDICINE MARKET SIZE, BY THERAPEUTIC PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 208. MALAYSIA NUCLEAR MEDICINE MARKET SIZE, BY BETA EMITTERS, 2018-2030 (USD MILLION)
  • TABLE 209. MALAYSIA NUCLEAR MEDICINE MARKET SIZE, BY BRACHYTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 210. MALAYSIA NUCLEAR MEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 211. MALAYSIA NUCLEAR MEDICINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 212. MALAYSIA NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC, 2018-2030 (USD MILLION)
  • TABLE 213. MALAYSIA NUCLEAR MEDICINE MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
  • TABLE 214. MALAYSIA NUCLEAR MEDICINE MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 215. PHILIPPINES NUCLEAR MEDICINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 216. PHILIPPINES NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 217. PHILIPPINES NUCLEAR MEDICINE MARKET SIZE, BY PET, 2018-2030 (USD MILLION)
  • TABLE 218. PHILIPPINES NUCLEAR MEDICINE MARKET SIZE, BY SPECT, 2018-2030 (USD MILLION)
  • TABLE 219. PHILIPPINES NUCLEAR MEDICINE MARKET SIZE, BY THERAPEUTIC PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 220. PHILIPPINES NUCLEAR MEDICINE MARKET SIZE, BY BETA EMITTERS, 2018-2030 (USD MILLION)
  • TABLE 221. PHILIPPINES NUCLEAR MEDICINE MARKET SIZE, BY BRACHYTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 222. PHILIPPINES NUCLEAR MEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 223. PHILIPPINES NUCLEAR MEDICINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 224. PHILIPPINES NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC, 2018-2030 (USD MILLION)
  • TABLE 225. PHILIPPINES NUCLEAR MEDICINE MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
  • TABLE 226. PHILIPPINES NUCLEAR MEDICINE MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 227. SINGAPORE NUCLEAR MEDICINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 228. SINGAPORE NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 229. SINGAPORE NUCLEAR MEDICINE MARKET SIZE, BY PET, 2018-2030 (USD MILLION)
  • TABLE 230. SINGAPORE NUCLEAR MEDICINE MARKET SIZE, BY SPECT, 2018-2030 (USD MILLION)
  • TABLE 231. SINGAPORE NUCLEAR MEDICINE MARKET SIZE, BY THERAPEUTIC PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 232. SINGAPORE NUCLEAR MEDICINE MARKET SIZE, BY BETA EMITTERS, 2018-2030 (USD MILLION)
  • TABLE 233. SINGAPORE NUCLEAR MEDICINE MARKET SIZE, BY BRACHYTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 234. SINGAPORE NUCLEAR MEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 235. SINGAPORE NUCLEAR MEDICINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 236. SINGAPORE NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC, 2018-2030 (USD MILLION)
  • TABLE 237. SINGAPORE NUCLEAR MEDICINE MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
  • TABLE 238. SINGAPORE NUCLEAR MEDICINE MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 239. SOUTH KOREA NUCLEAR MEDICINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 240. SOUTH KOREA NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 241. SOUTH KOREA NUCLEAR MEDICINE MARKET SIZE, BY PET, 2018-2030 (USD MILLION)
  • TABLE 242. SOUTH KOREA NUCLEAR MEDICINE MARKET SIZE, BY SPECT, 2018-2030 (USD MILLION)
  • TABLE 243. SOUTH KOREA NUCLEAR MEDICINE MARKET SIZE, BY THERAPEUTIC PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 244. SOUTH KOREA NUCLEAR MEDICINE MARKET SIZE, BY BETA EMITTERS, 2018-2030 (USD MILLION)
  • TABLE 245. SOUTH KOREA NUCLEAR MEDICINE MARKET SIZE, BY BRACHYTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 246. SOUTH KOREA NUCLEAR MEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 247. SOUTH KOREA NUCLEAR MEDICINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 248. SOUTH KOREA NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC, 2018-2030 (USD MILLION)
  • TABLE 249. SOUTH KOREA NUCLEAR MEDICINE MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
  • TABLE 250. SOUTH KOREA NUCLEAR MEDICINE MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 251. TAIWAN NUCLEAR MEDICINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 252. TAIWAN NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 253. TAIWAN NUCLEAR MEDICINE MARKET SIZE, BY PET, 2018-2030 (USD MILLION)
  • TABLE 254. TAIWAN NUCLEAR MEDICINE MARKET SIZE, BY SPECT, 2018-2030 (USD MILLION)
  • TABLE 255. TAIWAN NUCLEAR MEDICINE MARKET SIZE, BY THERAPEUTIC PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 256. TAIWAN NUCLEAR MEDICINE MARKET SIZE, BY BETA EMITTERS, 2018-2030 (USD MILLION)
  • TABLE 257. TAIWAN NUCLEAR MEDICINE MARKET SIZE, BY BRACHYTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 258. TAIWAN NUCLEAR MEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 259. TAIWAN NUCLEAR MEDICINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 260. TAIWAN NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC, 2018-2030 (USD MILLION)
  • TABLE 261. TAIWAN NUCLEAR MEDICINE MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
  • TABLE 262. TAIWAN NUCLEAR MEDICINE MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 263. THAILAND NUCLEAR MEDICINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 264. THAILAND NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 265. THAILAND NUCLEAR MEDICINE MARKET SIZE, BY PET, 2018-2030 (USD MILLION)
  • TABLE 266. THAILAND NUCLEAR MEDICINE MARKET SIZE, BY SPECT, 2018-2030 (USD MILLION)
  • TABLE 267. THAILAND NUCLEAR MEDICINE MARKET SIZE, BY THERAPEUTIC PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 268. THAILAND NUCLEAR MEDICINE MARKET SIZE, BY BETA EMITTERS, 2018-2030 (USD MILLION)
  • TABLE 269. THAILAND NUCLEAR MEDICINE MARKET SIZE, BY BRACHYTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 270. THAILAND NUCLEAR MEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 271. THAILAND NUCLEAR MEDICINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 272. THAILAND NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC, 2018-2030 (USD MILLION)
  • TABLE 273. THAILAND NUCLEAR MEDICINE MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
  • TABLE 274. THAILAND NUCLEAR MEDICINE MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 275. VIETNAM NUCLEAR MEDICINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 276. VIETNAM NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 277. VIETNAM NUCLEAR MEDICINE MARKET SIZE, BY PET, 2018-2030 (USD MILLION)
  • TABLE 278. VIETNAM NUCLEAR MEDICINE MARKET SIZE, BY SPECT, 2018-2030 (USD MILLION)
  • TABLE 279. VIETNAM NUCLEAR MEDICINE MARKET SIZE, BY THERAPEUTIC PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 280. VIETNAM NUCLEAR MEDICINE MARKET SIZE, BY BETA EMITTERS, 2018-2030 (USD MILLION)
  • TABLE 281. VIETNAM NUCLEAR MEDICINE MARKET SIZE, BY BRACHYTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 282. VIETNAM NUCLEAR MEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 283. VIETNAM NUCLEAR MEDICINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 284. VIETNAM NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC, 2018-2030 (USD MILLION)
  • TABLE 285. VIETNAM NUCLEAR MEDICINE MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
  • TABLE 286. VIETNAM NUCLEAR MEDICINE MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 287. EUROPE, MIDDLE EAST & AFRICA NUCLEAR MEDICINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 288. EUROPE, MIDDLE EAST & AFRICA NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 289. EUROPE, MIDDLE EAST & AFRICA NUCLEAR MEDICINE MARKET SIZE, BY PET, 2018-2030 (USD MILLION)
  • TABLE 290. EUROPE, MIDDLE EAST & AFRICA NUCLEAR MEDICINE MARKET SIZE, BY SPECT, 2018-2030 (USD MILLION)
  • TABLE 291. EUROPE, MIDDLE EAST & AFRICA NUCLEAR MEDICINE MARKET SIZE, BY THERAPEUTIC PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 292. EUROPE, MIDDLE EAST & AFRICA NUCLEAR MEDICINE MARKET SIZE, BY BETA EMITTERS, 2018-2030 (USD MILLION)
  • TABLE 293. EUROPE, MIDDLE EAST & AFRICA NUCLEAR MEDICINE MARKET SIZE, BY BRACHYTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 294. EUROPE, MIDDLE EAST & AFRICA NUCLEAR MEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 295. EUROPE, MIDDLE EAST & AFRICA NUCLEAR MEDICINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 296. EUROPE, MIDDLE EAST & AFRICA NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC, 2018-2030 (USD MILLION)
  • TABLE 297. EUROPE, MIDDLE EAST & AFRICA NUCLEAR MEDICINE MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
  • TABLE 298. EUROPE, MIDDLE EAST & AFRICA NUCLEAR MEDICINE MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 299. EUROPE, MIDDLE EAST & AFRICA NUCLEAR MEDICINE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 300. DENMARK NUCLEAR MEDICINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 301. DENMARK NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 302. DENMARK NUCLEAR MEDICINE MARKET SIZE, BY PET, 2018-2030 (USD MILLION)
  • TABLE 303. DENMARK NUCLEAR MEDICINE MARKET SIZE, BY SPECT, 2018-2030 (USD MILLION)
  • TABLE 304. DENMARK NUCLEAR MEDICINE MARKET SIZE, BY THERAPEUTIC PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 305. DENMARK NUCLEAR MEDICINE MARKET SIZE, BY BETA EMITTERS, 2018-2030 (USD MILLION)
  • TABLE 306. DENMARK NUCLEAR MEDICINE MARKET SIZE, BY BRACHYTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 307. DENMARK NUCLEAR MEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 308. DENMARK NUCLEAR MEDICINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 309. DENMARK NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC, 2018-2030 (USD MILLION)
  • TABLE 310. DENMARK NUCLEAR MEDICINE MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
  • TABLE 311. DENMARK NUCLEAR MEDICINE MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 312. EGYPT NUCLEAR MEDICINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 313. EGYPT NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 314. EGYPT NUCLEAR MEDICINE MARKET SIZE, BY PET, 2018-2030 (USD MILLION)
  • TABLE 315. EGYPT NUCLEAR MEDICINE MARKET SIZE, BY SPECT, 2018-2030 (USD MILLION)
  • TABLE 316. EGYPT NUCLEAR MEDICINE MARKET SIZE, BY THERAPEUTIC PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 317. EGYPT NUCLEAR MEDICINE MARKET SIZE, BY BETA EMITTERS, 2018-2030 (USD MILLION)
  • TABLE 318. EGYPT NUCLEAR MEDICINE MARKET SIZE, BY BRACHYTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 319. EGYPT NUCLEAR MEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 320. EGYPT NUCLEAR MEDICINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 321. EGYPT NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC, 2018-2030 (USD MILLION)
  • TABLE 322. EGYPT NUCLEAR MEDICINE MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
  • TABLE 323. EGYPT NUCLEAR MEDICINE MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 324. FINLAND NUCLEAR MEDICINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 325. FINLAND NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 326. FINLAND NUCLEAR MEDICINE MARKET SIZE, BY PET, 2018-2030 (USD MILLION)
  • TABLE 327. FINLAND NUCLEAR MEDICINE MARKET SIZE, BY SPECT, 2018-2030 (USD MILLION)
  • TABLE 328. FINLAND NUCLEAR MEDICINE MARKET SIZE, BY THERAPEUTIC PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 329. FINLAND NUCLEAR MEDICINE MARKET SIZE, BY BETA EMITTERS, 2018-2030 (USD MILLION)
  • TABLE 330. FINLAND NUCLEAR MEDICINE MARKET SIZE, BY BRACHYTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 331. FINLAND NUCLEAR MEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 332. FINLAND NUCLEAR MEDICINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 333. FINLAND NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC, 2018-2030 (USD MILLION)
  • TABLE 334. FINLAND NUCLEAR MEDICINE MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
  • TABLE 335. FINLAND NUCLEAR MEDICINE MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 336. FRANCE NUCLEAR MEDICINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 337. FRANCE NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 338. FRANCE NUCLEAR MEDICINE MARKET SIZE, BY PET, 2018-2030 (USD MILLION)
  • TABLE 339. FRANCE NUCLEAR MEDICINE MARKET SIZE, BY SPECT, 2018-2030 (USD MILLION)
  • TABLE 340. FRANCE NUCLEAR MEDICINE MARKET SIZE, BY THERAPEUTIC PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 341. FRANCE NUCLEAR MEDICINE MARKET SIZE, BY BETA EMITTERS, 2018-2030 (USD MILLION)
  • TABLE 342. FRANCE NUCLEAR MEDICINE MARKET SIZE, BY BRACHYTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 343. FRANCE NUCLEAR MEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 344. FRANCE NUCLEAR MEDICINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 345. FRANCE NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC, 2018-2030 (USD MILLION)
  • TABLE 346. FRANCE NUCLEAR MEDICINE MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
  • TABLE 347. FRANCE NUCLEAR MEDICINE MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 348. GERMANY NUCLEAR MEDICINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 349. GERMANY NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 350. GERMANY NUCLEAR MEDICINE MARKET SIZE, BY PET, 2018-2030 (USD MILLION)
  • TABLE 351. GERMANY NUCLEAR MEDICINE MARKET SIZE, BY SPECT, 2018-2030 (USD MILLION)
  • TABLE 352. GERMANY NUCLEAR MEDICINE MARKET SIZE, BY THERAPEUTIC PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 353. GERMANY NUCLEAR MEDICINE MARKET SIZE, BY BETA EMITTERS, 2018-2030 (USD MILLION)
  • TABLE 354. GERMANY NUCLEAR MEDICINE MARKET SIZE, BY BRACHYTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 355. GERMANY NUCLEAR MEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 356. GERMANY NUCLEAR MEDICINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 357. GERMANY NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC, 2018-2030 (USD MILLION)
  • TABLE 358. GERMANY NUCLEAR MEDICINE MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
  • TABLE 359. GERMANY NUCLEAR MEDICINE MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 360. ISRAEL NUCLEAR MEDICINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 361. ISRAEL NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 362. ISRAEL NUCLEAR MEDICINE MARKET SIZE, BY PET, 2018-2030 (USD MILLION)
  • TABLE 363. ISRAEL NUCLEAR MEDICINE MARKET SIZE, BY SPECT, 2018-2030 (USD MILLION)
  • TABLE 364. ISRAEL NUCLEAR MEDICINE MARKET SIZE